Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetes

BACKGROUND: Overweight or obesity contributes to the development of type 2 diabetes mellitus (T2DM) and increases cardiovascular risk. Exenatide, a glucagon-like peptide-1 receptor agonist, significantly reduces glycated hemoglobin (A1C) and body weight and improves cardiovascular risk markers in pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Blonde, Lawrence, Pencek, Richard, MacConell, Leigh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4324846/
https://www.ncbi.nlm.nih.gov/pubmed/25645567
http://dx.doi.org/10.1186/s12933-014-0171-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4324846/
https://www.ncbi.nlm.nih.gov/pubmed/25645567
http://dx.doi.org/10.1186/s12933-014-0171-2

Ejemplares similares